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Initial evaluation of novel 
preparations of Bordetella
avium by determination of 
antibody-response titers
Joel L. Gallagher*, Stacy E. Higgins†, Luc Berghman§, Billy M. Hargis‡
ABSTRACT
The efficacy of killed vaccines generally is not equal to live vaccines. However, due to safety and
ease of production, they remain a vital part of controlling and preventing diseases. In this study,
the immune response to four different vaccination preparation techniques for the agent of bor-
detellosis of turkeys, Bordetella avium (BA), was compared. Preparation/inactivation techniques
included (1) formalin inactivation, (2) opsonization of formalin-inactivated BA, (3) buffered
acetic-acid BA inactivation, or (4) opsonization of buffered acetic-acid-inactivated BA. Non-
adjuvated suspensions containing equal antigen mass were administered subcutaneously (0.2
mL) at day-of-hatch in all cases. For each treatment (N=40/treatment), plasma samples were
obtained on d 6, 10, and 21. Specific antibody titer was determined by enzyme-linked
immunosorbent assay (ELISA). Results were analyzed by percentage of responders, calculated by
determination of sample-to-positive (S/P) ratio. At d 6, the formalin-killed vaccination caused
the most rapid response with significantly higher S/P ratios than other treatments. At d 10 there
were no significant differences between the treatments. By d 21, formalin-inactivated antigen
produced the highest percentage of responders. In this preliminary experiment, neither buffered
acetic-acid BA inactivation nor opsonization of inactivated BA antigen improved turkey poult
responsiveness to this pathogen.
* Joel Gallagher is a senior majoring in biology.
† Stacy Higgins is a Ph.D. candidate in the Department of Poultry Science
§ Luc Berghman is an associate professor in the Department of Poultry Science at  Texas A&M University in College Station, Texas.
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INTRODUCTION
Bordetellosis is an extremely contagious poultry dis-
ease caused by the organism Bordetella avium (BA), a
small, Gram-negative bacterium that colonizes in the cil-
iated epithelium of the trachea of young turkeys
(poults). The disease is characterized by interference
with the respiratory mucosa and symptoms include
sneezing and oculonasal emissions (Skeeles and Arp,
1997). Although it is difficult to determine the precise
economic loss to the poultry industry because the dis-
ease is often coupled with mortality and morbidity due
to secondary infections, estimates of economic losses
due to reduced body weight, reduced feed efficiency, and
animal mortality are in the millions of dollars each year
(USDA ARS, 2002).
Once infection has become apparent, treatments for
bordetellosis have focused chiefly on antibiotic treat-
ment rather than preventative care. This approach is
slowly being phased out as the industry is moving away
from using antibiotics in animals intended for human
consumption (USDA ARS, 2002). Additionally, the
emergence of antibiotic resistance has become a major
concern worldwide. Indeed, several years ago in a docu-
ment outlining strategies against microbial antibiotic
resistance, the European Union labeled the situation as a
“public health priority” and addressed the problem by
taking steps to restrict antibiotic use to serious humans
and animal health problems only (Commission of the
European Communities, 2001).
Various studies have focused on treating the problem
only after it arises with such treatments as the use of
niacin (Yersin, 1991) and a novel oxy-halogen formula
(Pardue and Luiginbuhl, 1998), both of which are
administered through drinking water. Prevention in the
form of vaccination is certainly the most effective as well
as economic treatment, but current vaccines are not con-
sistently protective. One research team explored the idea
of passive immunity by isolating serum and tracheal
remnants from convalescent poults, which resulted in a
small reduction of adherence of B. avium to tracheal
mucosa (Arp and Hellwig, 1988). A temperature-sensi-
tive B. avium mutant known as ART-VAX, given via eye-
drop/oral and spray cabinet protocols, showed a reduced
severity of lesions although it failed to prevent infection
upon challenge (Houghten and Skeeles, 1987). A forma-
lin-inactivated bacterin also failed to produce consistent
and long-lasting results under a challenge model
(Hofstad and Jeska, 1985).
One promising method of vaccine production takes
advantage of immune complexes, which are formed dur-
ing an immune response to a foreign antigen through
the binding of highly specific antibodies to a specific
antigen. Introducing immune complexes to lymphoid
follicles is thought to promote the creation of germinal
centers, which in turn leads to the proliferation of mem-
ory B cells. This can result in increased antibody pro-
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duction (Nayak et al., 1999; Nie et al., 1997; Kunkl and
Klaus, 1981).
Although the precise mechanism remains uncertain,
studies that examined the effects of immune complexes
made with immunoglobulin-E (IgE) hypothesized that
the increased antigen-specific response is due to efficient
absorption of the complexes into B-cells via a low-affin-
ity IgE receptor located on the B-cell surface. They also
observed that the complexes specifically led to an
increase in the number of immunoglobulin-G (IgG)-
secreting cells, leading to the possibility of the existence
of a secondary mode of antibody response that occurs
without the need for priming (Westman et al., 1997).
Complexes composed of equal amounts of antigen and
antibody or a slight surplus of antigen had greater suc-
cess at generating memory B-cells than antigen alone.
The constant portion of the antibody appeared to be the
key; the variable portion of the antibody protein proved
to be less effective (Klaus and Humphrey, 1978).
Immune complexes may also play a role in controlling
the release of antigens by increasing the amount of time
that immune cells are exposed to the antigen (Sah and
Chien, 1996). Additional studies have shown that
immune complexes resulted in a stronger localized
response compared to the uncomplexed controls (Levy
et al., 2001).
This concept of immune complexes has been incor-
porated into the development of a vaccine for infectious
bursal disease virus (IBDV). Field trials have proven
somewhat successful. Jeurissen et al. (1998) found that
virus detection in the IBDV/complex group was delayed
for 5 d compared to the IBDV group, and that germinal
centers were much more prevalent in the spleens of the
IBDV/complex chickens, demonstrating higher activity
of B-lymphocytes in the IBDV/complex group.
Although both treatments lead to depletion of B-cells in
the bursal follicles, the reduction was less severe at all
time points in the IBDV/complex group (Jeurissen et al.,
1998). Using reverse-transcriptase PCR to detect the
presence of IBDV in trials with the vaccine, it was found
that the viral load peaked at d 17 for the SPF chickens
and d 21 for the maternally immune broilers, eventually
disappearing altogether as seroconversion occurred
(Ivan et al., 2005). Another research team concluded that
the IBDV/complex vaccine can be administered quite
successfully as early as d 1 despite the presence of vari-
able levels of maternal antibodies (Haddad et al., 1997).
Another area of vaccine production that can be
improved upon is the inactivation method of killed vac-
cines. They are usually created by growing the organism
of interest, and then adding formalin to ensure the
organism is killed prior to administration via injection.
Numerous vaccines have been created in this fashion,
ranging from the Salk polio vaccine to diphtheria and
tetanus vaccines. However, formalin will often cross-
link proteins on the surface of cells through hydrox-
ymethylene bridges and thus modify the three-dimen-
sional protein structure within 24-48 hours of exposure
(Metz et al., 2004; Werner et al., 2000; Rappuoli, 1997).
Therefore, the animals might produce antibodies to arti-
ficial epitopes formed by the crosslinks rather than anti-
bodies that are protective against live organisms during
an actual infection. It is necessary to preserve antigenic
structure in order to allow an adequate amount of anti-
gen to be present for an extended period of time on the
surface of dendritic follicular cells. This leads to the syn-
thesizing of a higher number of B-memory cells specific
to that antigen and hence a stronger immune response
(Regenmortel, 1992).
The tendency of formalin to alter antigenic epitopes
has been shown in several studies (Metz et al., 2003;
Nencioni et al., 1991), especially with pertussis vaccines
for humans. Clearly, formalin has the potential to alter
the epitopes in a detrimental fashion. A more natural
deactivation method is needed in order to avoid the
potential outcomes associated with the use of formalin.
An ideal deactivating agent would retain intact bacterial
epitopes while inactivating the pathogen. Therefore, the
objective of this study was to manufacture a killed vac-
cine that could be administered with a single injection
and produce a strong, long-lasting immune response.
MATERIALS AND METHODS
Production of antibodies for immune complexes
Turkey-origin antibodies (Ab) were generated for use
in these studies. Briefly, turkeys were injected twice with
inactivated BA at 6 (1010 cfu) and 9 (105 cfu) weeks of
age. Serum obtained 10 d after the final injection was
used for this experiment. Agar gel immunodiffusion
(AGID) assays were used to estimate the relative titers for
standardization during the opsonization process.
Vaccine production and administration
Four groups of vaccines were created – two batches
killed with 3% formalin and two additional batches
killed with 10% acetic-acid. One formalin and one
acetic-acid group were complexed with the harvested
turkey antibodies (Ab), while the two remaining forma-
lin and acetic-acid groups were left uncomplexed (Table
1). The acetic-acid was buffered with the addition of
NaOH to a pH of 4.75, which is near the pKa of acetic-
acid. To create the complexed vaccines, B. avium was
killed using methods described above, and dilutions of
Ab were combined with 100 µl of B. avium at a concen-
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tration of 109 cfu/ml on slides, stained with Trypan blue,
and examined in a microscope. The least Ab dilution
that displayed evidence of immune complexes with
some loose bacteria present was selected for opsoniza-
tion. Once the dilution was determined, the formalin-
complexed and acetic-acid-complexed vaccines were
prepared. A fifth group consisted of negative controls,
which were injected with either a formalin or acetic-acid
vehicle (0.2 ml/poult).
The vaccines were administered to poults on the day
of hatch by subcutaneous injection (0.2 ml/poult at 5.68
x 109 cfu inactivated). Each group, consisting of 40
tagged poults each, was kept in separate pens furnished
with heat lamps, feed, and water arranged in similar
locations in each pen. Blood samples were obtained at d
6, 10, and 21 using 22-gauge needles and 5-ml syringes.
In order to minimize clotting, heparin was used at a con-
centration of 20 units/ml. Each sample was centrifuged
at 1500 RPM for 10 min and the plasma was isolated and
stored in 1.5-ml microcentrifuge tubes at –20°C.
Titer determination
The antibody titer of each group at each time point
was determined using an ELISA. The 96-well plates for
the test were prepared and stored according to Hopkins
et al. (1988), using 0.1M carbonate/bicarbonate buffer
rather than 0.05M. Each plate contained triplicates of
seven identical positive dilutions of serum from the
hyperimmunized birds and triplicates of a negative dilu-
tion composed of pooled sera from the control group
samples. These positives and negatives served as internal
standards in each plate (Table 2).
A preliminary assay was conducted with selected
dilutions of unknown samples to determine the appro-
priate dilution factor. From this preliminary assay, it was
determined that a dilution of 1:25 provided the most
reliable results while maintaining a feasible development
time. Therefore, each unknown sample was diluted 25-
fold and placed as duplicates into the remaining wells on
each plate. The results from each plate were normalized
using the internal standards and the absorption values of
each of the unknowns were averaged. These values rep-
resented the relative titers between the samples. These
relative titers provided a numerical measure of the
amount of antibody present. In order to put the results
into a more easily understood value, the sample-to-pos-
itive (S/P) ratio of each sample was calculated according
to the below equation:
where NCx represents the negative control mean and
PCx represents the positive control mean. It was decid-
ed to use the 1:16,000 positive dilutions because it gave
absorption readings around 2 absorption units.
Readings around 2 absorption units indicated that those
samples were on a part of the standard curve graph that
was less sigmoidal and more linear. Using a more linear
portion of the graph is more useful for titer predication
purposes. This technique is widely used in various
immunological contexts (Hendrick et al., 2005; Nagy et
al., 2002). S/P ratios can even act as a rough estimate of
the level of antibody in the serum (Snelson, 2003).
The mean, standard deviation, standard error, and
probability were calculated using SAS (SAS, Inc., Cary,
N.C.) statistics software to determine significant differ-
ences among groups. Differences are reported at P<0.05.
RESULTS AND DISCUSSION
S/P Ratios
Those samples that displayed a positive S/P ratio were
said to have had an immune reaction to the vaccines.
Alternatively, those with a negative S/P ratio were said to
have little or no reaction. The graphs for each day
depicted both the average positive and total average S/P
ratio for each group in order to compare both the aver-
ages of those that responded and the total averages of
responders and non-responders alike.
Percent of Positive S/P Ratios
All groups reacted to the vaccines to some extent (Fig.
1). More birds initially reacted to the formalin-inacti-
vated group (F) compared to the acetic-acid-inactivated
group (AA). However, by d 21, 50% of the acetic-acid
group had responded. No obvious differences were evi-
dent until d 21. At d 21, percentages generated by both
formalin groups (F/F+Ab) were higher than those
induced by both acetic-acid groups (AA/AA+Ab), reach-
ing levels commonly believed to be necessary for flock
immunity. The formalin-complexed (F) group on d 21
had statistically higher coverage than either of the acetic-
acid groups (AA/AA+Ab), although results were not sta-
tistically different than formalin inactivation (F) alone.
Day 6 S/P Ratios
It is possible that the negative values displayed in the
S/P ratio averages could be a result of the presence of
non-specific binding sites on the B. avium bacteria for
the constant (Fc) portion of antibodies (Fig 2).
However, this possibility was not evaluated in our study.
Although all groups had some negative S/P ratio aver-
ages, the formalin group (F) was significantly higher
than the acetic-acid-complexed group (AA+Ab) and not
significantly different from the other two groups. The
acetic-acid group (AA) and formalin-complexed group







groups. Of the birds that had a positive S/P ratio and
hence did respond to the vaccine, no significance was
observed in any of the groups.
Day 10 S/P Ratios
The averages on d 10, where intermediate responses
were anticipated, were not elucidating. No significant
differences existed in either the total averages or positive
averages in any of the groups (Fig. 3). Due to the simi-
larity of the formalin/formalin-complexed and acetic-
acid/acetic-acid-complexed averages, especially the posi-
tive averages, it appears that the addition of immune
complexes did nothing to aid in the immunological reac-
tion to the vaccine.
Day 21 S/P Ratios
With regard to the positive S/P ratio averages, the for-
malin and formalin-complexed groups exhibited signif-
icantly higher averages than the acetic-acid-inactivated
group. The acetic-acid-complexed group was not signif-
icantly different from any group. Including all birds
increased the interpretability of these results. The for-
malin-complexed and formalin groups both featured
significantly higher averages than the acetic-acid-com-
plexed and acetic-acid groups (Figure 4).
The formalin-inactivated vaccines, which approached
80% positive antibody response, were superior to the
acetic-acid-inactivated vaccines by d 21. Addition of
immune complexes was not of any benefit. From this
experiment, it does not appear that either opsonization
or the acetic-acid method for inactivation of BA for vac-
cine generation offer improved methods for inactivated
BA vaccination of turkeys.
Development of an improved vaccine for Bordetella
avium would have implications on all species that are
susceptible to infection by Bordetella species, including
canines and humans. Improvement of killed vaccines in
general would have repercussions for many of our cur-
rent vaccines for various animal immunizations.
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Fig 1. Percentages of each group with positive S/P ratios at day 6, 10 or 21. Histograms with different letters are significantly (p<0.05) different.
Abbreviation of treatments are as follows: AA = acetic-acid, AA+Ab = acetic-acid-complexed, F = formalin, F+Ab = formalin-complexed.
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Fig 4. Averages of all S/P ratios and positive S/P ratios in each group as measured on day 21. Histograms with different letters are significantly (p<0.05) different.
Abbreviation of treatments are as follows: AA = acetic-acid, AA+Ab = acetic-acid-complexed, F = formalin, F+Ab = formalin-complexed.
Fig 3. Averages of all S/P ratios and positive S/P ratios in each group as measured on day 10. Differences between groups were not significant (p>0.05).
Abbreviation of treatments are as follows: AA = acetic-acid, AA+Ab = acetic-acid-complexed, F = formalin, F+Ab = formalin-complexed.
Fig 2. Averages of all S/P ratios and positive S/P ratios in each group as measured on day 6. Histograms with different letters are significantly (p<0.05) different.
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Table 1. Production process of the four vaccines and controls.
Grow B. avium (1010 CFU/ml) 0.9% Saline
↓ ↓ ↓ ↓
Kill using 10% AA @ pH 4.2-4.5 (AA) Kill using 3% formalin (F)





↓ ↓ ↓ ↓ ↓ ↓
Group 1
Complexed
Acetic acid AA+Ab
(Ba + Ab)
Group 2
Uncomplexed acetic acid
AA
(Ba only)
Group 3
Complexed formalin
F+Ab
(Ba + Ab)
Group 4
Uncomplexed formalin
F
(Ba only)
Group 5
Acetic acid
negative controls
(saline + AA)
Group 6
Formalin negative
controls
(saline + F)
